These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Ⅲ.The History of Developing Anticancer Drug for Urothelial Carcinoma and Future Issues]. Kojima T Gan To Kagaku Ryoho; 2021 Jan; 48(1):41-45. PubMed ID: 33468721 [No Abstract] [Full Text] [Related]
43. Interview with Dr Richard Sylvester: transition cell carcinoma of the bladder. Interview by Christine McKillop. Sylvester R Eur Urol; 2007 Jun; 51(6):1748-50. PubMed ID: 17374436 [No Abstract] [Full Text] [Related]
45. Laser treatment of bladder cancer. Smith JA Semin Urol; 1985 Feb; 3(1):2-9. PubMed ID: 3159062 [No Abstract] [Full Text] [Related]
46. A phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder. Blackledge G; Roberts JT; Kaye S; Taylor R; Williams J; de Stavola B; Uscinska B Eur J Cancer Clin Oncol; 1989 Feb; 25(2):391-2. PubMed ID: 2702992 [No Abstract] [Full Text] [Related]
47. Chemotherapy of bladder cancer: current progress. Murphy GP N Y State J Med; 1977 Oct; 77(12):1889-95. PubMed ID: 270015 [No Abstract] [Full Text] [Related]
48. [Treatment of superficial transitional cell carcinoma of the bladder]. Nissenkorn J Harefuah; 1982 May; 102(10):436-8. PubMed ID: 7160676 [No Abstract] [Full Text] [Related]
49. Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. Tickoo SK; Milowsky MI; Dhar N; Dudas ME; Gallagher DJ; Al-Ahmadie H; Gopalan A; Fine SW; Ishill N; Bajorin DF; Reuter VE BJU Int; 2011 Mar; 107(5):844-849. PubMed ID: 20707797 [TBL] [Abstract][Full Text] [Related]
50. Hypothalamitis and severe hypothalamic dysfunction associated with anti-programmed cell death ligand 1 antibody treatment. Tshuma N; Glynn N; Evanson J; Powles T; Drake WM Eur J Cancer; 2018 Nov; 104():247-249. PubMed ID: 30377030 [No Abstract] [Full Text] [Related]
51. Urothelial carcinoma with squamous differentiation: response to chemotherapy and radiation. Clark PE Urol Oncol; 2015 Oct; 33(10):434-6. PubMed ID: 26278365 [TBL] [Abstract][Full Text] [Related]